spacer
home > ebr > spring 2018 > at a glance
PUBLICATIONS
European Biopharmaceutical Review

At a Glance

Personalised medicine means that medical treatment can be tailored towards an individual after a disease has been – hopefully correctly – diagnosed. The treatment should take multiple factors such as age, weight, lifestyle, and, ultimately, genomic information into account. The more precisely and reliably this can be done, the better the patient should respond to the therapy without any unwanted adverse effects.

Nowadays, the term ‘personalised medicine’ is almost exclusively associated with next generation sequencing (NGS) or whole genome sequencing (WGS), respectively. This means one essentially takes a sample (a simple stick in the mouth serves this purpose well) and sends it to their favourite NGS company, which will probably cost less than €1,000, and then they get a long list of diseases and a probability that they will develop one of these diseases or they already have one or multiple diseases. However, that is not the whole story, and, probably, the more interesting story starts there.

A Brief History of WGS

At the beginning in 1990, sequencing the entire human genome for the first time took 13 years and $3 billion. Nine years later, 69 more human genomes were sequenced. In 2016, the University of Toronto launched a project to sequence 10,000 genomes within one year (1). As of the beginning of 2018, the 100,000 genomes project has reached almost 40,000 sequenced genomes and is expected to reach its goal by end of the same year (2). When you look at the cost for sequencing a genome (see Figure 1, page 54, noting the logarithmic y-scale), it becomes clear what a tremendous progress the whole technique has made over the past few years.

Read full article from PDF >>

Rate this article You must be a member of the site to make a vote.  
Average rating:
0
     

There are no comments in regards to this article.

spacer
Guenther Proll is Co-Founder and Managing Director at Biametrics and has more than 18 years’ experience in optical biosensing. His work is focused on the characterisation and development of optical transduction technologies, spatially resolved surface chemistry on diverse substrates, and multianalyte/multiplex assay developments. Guenther holds a diploma in technical biology from the University of Stuttgart, Germany, and a PhD in physical chemistry from the Eberhard Karls University of Tuebingen, Germany.
spacer
Guenther Proll
spacer
spacer
Print this page
Send to a friend
Privacy statement
News and Press Releases

3P Biopharmaceuticals initiates partnership with American Biotech Zhittya for Parkinson’s disease treatment

3P and Zhittya began their relationship at the beginning of 2019 with 3P being selected as the CDMO to transfer the process for scaling up and performing cGMP manufacturing for clinical studies. After successfully achieving transfer of the process, 3P anticipates manufacturing of the first cGMP batch by the second quarter of 2020.
More info >>

White Papers

Sourcing Commercial Drugs for Clinical Trials: US vs. EU Understanding the Differences

Myoderm

Sourcing commercial drugs for clinical trials is a dynamic process. There are many factors to consider: single source or regional sourcing, strategy, price, supply availability, lead times, and documentation are just a few. In the past, there were fewer clinical trials that required commercial drug sourcing, so demand was not as high. Today, the demand for commercial drugs in clinical trials has greatly increased and, as a result, inventory is tighter, orders are monitored more closely by manufacturers, and lead times have increased. This report highlights the key differences in sourcing from the US and EU.
More info >>

 
Industry Events

CPhI & P-MEC India

26-28 November 2019, India Expo Centre, Greater Noida, Delhi NCR, India

As the pharma industry looks increasingly towards India forhigh quality, low   cost pharma solutions, CPhI & P-MEC Indiais the ideal event for companies wanting to pick up on the latest trends and innovations the market has to offer. At CPhI & P-MEC India, you will meet the movers and shakers from India’s pharma machinery, technology and ingredients industries, giving you a competitive advantage that will help grow your business.
More info >>

 

 

©2000-2011 Samedan Ltd.
Add to favourites

Print this page

Send to a friend
Privacy statement